Aberdeen Group plc Has $3.29 Million Stake in Dyne Therapeutics, Inc. $DYN

Key Points

• Aberdeen Group plc significantly increased its stake in Dyne Therapeutics by 1,119.2%, acquiring 288,783 additional shares for a total ownership of approximately 0.28% valued at $3.29 million.
• Several analysts adjusted their price targets for Dyne Therapeutics, with Oppenheimer lowering its target from $34 to $13, while two analysts rated the stock as a Strong Buy.
• Dyne Therapeutics reported a quarterly loss of ($0.97) earnings per share, exceeding the consensus estimate of ($0.99), indicating some operational resilience amidst potential challenges.

Aberdeen Group plc increased its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 1,119.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 314,586 shares of the company's stock after buying an additional 288,783 shares during the quarter. Aberdeen Group plc owned about 0.28% of Dyne Therapeutics worth $3,291,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd boosted its stake in Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after purchasing an additional 2,446 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Dyne Therapeutics during the 4th quarter valued at $50,000. E Fund Management Co. Ltd. boosted its stake in Dyne Therapeutics by 16.2% during the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock valued at $144,000 after purchasing an additional 1,923 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Dyne Therapeutics during the 1st quarter valued at $179,000. Finally, Arizona State Retirement System boosted its stake in Dyne Therapeutics by 9.2% during the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after purchasing an additional 1,481 shares in the last quarter. 96.68% of the stock is owned by institutional investors.

Dyne Therapeutics Stock Up 2.9%

Shares of DYN traded up $0.38 during mid-day trading on Tuesday, reaching $13.38. The company's stock had a trading volume of 2,523,201 shares, compared to its average volume of 3,128,693. The business has a fifty day moving average of $10.27 and a 200 day moving average of $11.16. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -3.47 and a beta of 1.08. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $46.26. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. As a group, analysts forecast that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO John Cox acquired 100,000 shares of the business's stock in a transaction that occurred on Monday, July 14th. The stock was acquired at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the acquisition, the chief executive officer owned 242,179 shares in the company, valued at approximately $2,206,250.69. The trade was a 70.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 20.77% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on DYN shares. Robert W. Baird reduced their price objective on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a research note on Wednesday, June 18th. Oppenheimer reduced their price objective on Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating for the company in a research note on Wednesday, August 6th. Sanford C. Bernstein started coverage on Dyne Therapeutics in a research note on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price objective for the company. JPMorgan Chase & Co. reduced their price objective on Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating for the company in a research note on Tuesday, July 15th. Finally, Jones Trading started coverage on Dyne Therapeutics in a research note on Thursday, June 26th. They set a "buy" rating and a $30.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $34.07.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.